摘要
细胞周期蛋白依赖性激酶(cyclin dependent kinase,CDK)4/6抑制剂在阻止肿瘤生长、疾病发展和提高存活率方面显示出显著的效果,是目前抗肿瘤药物研发的热点,临床上已用于乳腺癌和非小细胞肺癌的治疗。CDK4/6在消化道肿瘤中有扩增和过度表达,CDK4/6抑制剂在消化道肿瘤中已陆续展开临床试验,本文就近期CDK4/6抑制剂在食管癌、胃癌、结直肠癌中的临床试验情况进行综述。
Cyclin dependent kinase(CDK)4/6 inhibitors have shown significant effects in preventing tumor growth, disease development, and improving survival rates. They are currently a hot spot in the research and development of anti-cancer drugs and have been clinically applied in the treatment of breast cancer and non-small cell lung cancer. CDK4/6 is amplified and overexpressed in gastrointestinal tumors. CDK4/6 inhibitors have been studied in gastrointestinal tumors. This article reviews the recent clinical trials of CDK4/6 inhibitors in esophageal cancer, gastric cancer, and colorectal cancer.
作者
刘艳华
王明权
朱伟英
卢燕君
王文佳
LIU Yanhua;WANG Mingquan;ZHU Weiying;LU Yanjun;WANG Wenjia(Hangzhou Simbos Pharm Co.,Ltd.,Hangzhou 311121,China;Hangzhou Kewan New Material Technology Co.,Ltd.,Lin’an 311305,China)
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2021年第18期2333-2336,共4页
Chinese Journal of Modern Applied Pharmacy
关键词
CDK4/6抑制剂
临床试验
食管癌
胃癌
结直肠癌
CDK4/6 inhibitors
clinical trial
esophageal cancer
gastric cancer
colorectal cancer